A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42) protein in ...

A new announcement from pharmaceutical company Roche has revealed the failure of a massive global Phase 3 trial testing its latest anti-amyloid Alzheimer's disease treatment. The failure marks another ...

Cerebrospinal fluid (CSF) is a clear and watery liquid that flows in and around the brain and spinal cord. Its functions include protecting parts of the nervous system, delivering nutrients and ...

The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal antibody that ...

The study characterized and compared the binding profile of various amyloid-beta (Ab)-directed antibodies to monomers, soluble oligomers and insoluble Ab fibrils. The results indicate that selectivity ...

Rare mutations in the amyloid precursor protein (APP) have previously been shown to be strongly associated with Alzheimer's disease (AD). Common genetic variants in this protein may also be linked to ...

Previous research has implicated fungi in chronic neurodegenerative conditions such as Alzheimer’s disease, but there is limited understanding of how these common microbes could be involved in the ...

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab helps ...